DK1489097T3 - Hæmmere af humant plasmin, der er afledt af kunitz-domæner, og nukleinsyrer, der koder for samme - Google Patents

Hæmmere af humant plasmin, der er afledt af kunitz-domæner, og nukleinsyrer, der koder for samme

Info

Publication number
DK1489097T3
DK1489097T3 DK04022346.3T DK04022346T DK1489097T3 DK 1489097 T3 DK1489097 T3 DK 1489097T3 DK 04022346 T DK04022346 T DK 04022346T DK 1489097 T3 DK1489097 T3 DK 1489097T3
Authority
DK
Denmark
Prior art keywords
nucleic acids
acids encoding
inhibitors
same
kunitz domains
Prior art date
Application number
DK04022346.3T
Other languages
English (en)
Inventor
William Markland
Robert Charles Ladner
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DK1489097T3 publication Critical patent/DK1489097T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/515—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics
    • C04B35/58—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides
    • C04B35/584—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides based on silicon nitride
    • C04B35/593—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides based on silicon nitride obtained by pressure sintering
    • C04B35/5935—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxide ceramics based on borides, nitrides, i.e. nitrides, oxynitrides, carbonitrides or oxycarbonitrides or silicides based on silicon nitride obtained by pressure sintering obtained by gas pressure sintering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ceramic Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Structural Engineering (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Amplifiers (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
DK04022346.3T 1994-01-11 1995-01-11 Hæmmere af humant plasmin, der er afledt af kunitz-domæner, og nukleinsyrer, der koder for samme DK1489097T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17965894A 1994-01-11 1994-01-11
US20826594A 1994-03-10 1994-03-10
EP95908460A EP0737207B1 (en) 1994-01-11 1995-01-11 Inhibitors of human plasmin derived from the kunitz domains

Publications (1)

Publication Number Publication Date
DK1489097T3 true DK1489097T3 (da) 2012-01-09

Family

ID=26875521

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04022346.3T DK1489097T3 (da) 1994-01-11 1995-01-11 Hæmmere af humant plasmin, der er afledt af kunitz-domæner, og nukleinsyrer, der koder for samme
DK95908460T DK0737207T3 (da) 1994-01-11 1995-01-11 Inhibitorer for humant plasmin afledt af Kunitz-domæner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK95908460T DK0737207T3 (da) 1994-01-11 1995-01-11 Inhibitorer for humant plasmin afledt af Kunitz-domæner

Country Status (10)

Country Link
US (11) US6010880A (da)
EP (2) EP0737207B1 (da)
JP (5) JP4137997B2 (da)
AT (2) ATE529444T1 (da)
CA (1) CA2180954C (da)
DE (1) DE69533544T2 (da)
DK (2) DK1489097T3 (da)
ES (2) ES2375561T3 (da)
PT (2) PT1489097E (da)
WO (1) WO1995018830A2 (da)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
ATE529444T1 (de) * 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
AU708394B2 (en) * 1995-06-07 1999-08-05 Novartis Vaccines And Diagnostics, Inc. Regulation of cytokine synthesis and release
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
HU226419B1 (en) 1996-03-11 2008-12-29 Aerovance Human bikunin
US6703484B2 (en) 1997-01-08 2004-03-09 Invitrogen Corporation Methods for production of proteins
US20060025329A1 (en) * 1997-02-06 2006-02-02 Todd Hembrough Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US20020076728A1 (en) * 1997-03-21 2002-06-20 Maclennan John Moore Engineering affinity ligands for macromolecules
US6087473A (en) * 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
EP1108029A1 (en) * 1998-09-03 2001-06-20 ZymoGenetics Kunitz domain polypeptide zkun6
US6380354B1 (en) 1998-09-03 2002-04-30 Zymogenetics, Inc. Kunitz domain polypeptide zkun6
US5994310A (en) * 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20030032146A1 (en) * 2001-07-10 2003-02-13 Dwulet Francis Edward Enzyme/tag binding and detection system
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
AU2003244516A1 (en) * 2002-02-07 2003-09-02 Novozymes Delta Limited Hiv inhibiting proteins
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT2311432E (pt) 2002-06-07 2015-02-09 Dyax Corp Polipeptídeos de domínio kunitz modificado e sua utilização para a redução de isquemia ou aparecimento de uma resposta inflamatória sistémica associada a um procedimento cirúrgico
DK1542710T3 (da) 2002-08-28 2012-10-15 Dyax Corp Fremgangsmåde til konservering af organer og væv
AU2004204095B2 (en) * 2003-01-07 2009-07-30 Dyax Corporation Kunitz domain library
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US20070020252A1 (en) * 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7740973B2 (en) * 2004-08-05 2010-06-22 General Motors Corporation Modular electrochemical power system
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006057997A2 (en) * 2004-11-22 2006-06-01 Dyax Corp. Plasmin-inhibitory therapies
EP2500031A3 (en) 2005-02-24 2012-12-26 Joslin Diabetes Center, Inc. Compositions and Methods for Treating Vascular Permeability
GB0521404D0 (en) * 2005-10-20 2005-11-30 Ares Trading Sa Kunitz domain containing protein
WO2007070372A2 (en) * 2005-12-09 2007-06-21 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
ES2661002T3 (es) * 2005-12-29 2018-03-27 The Regents Of The University Of California Procedimientos y composiciones relacionadas con el dominio Kunitz I mutante de TFPI-2
AU2013202021B2 (en) * 2005-12-29 2016-03-10 The Regents Of The University Of California Methods and compositions related to mutant Kunitz domain of TFPI-2
SI1981519T1 (en) 2005-12-29 2018-05-31 Dyax Corp. INHIBITION PROTEAZE
CA2635588C (en) 2005-12-30 2015-11-10 Dyax Corp. Metalloproteinase binding proteins
WO2007101602A2 (en) * 2006-03-08 2007-09-13 Bayer Healthcare Ag Chimeric kunitz domains and their use
WO2007106746A2 (en) * 2006-03-10 2007-09-20 Dyax Corp. Formulations for ecallantide
DK1854477T3 (da) * 2006-03-16 2016-11-28 Dyax Corp Peptidinhibitorer af plasmakallikrein til anvendelse til behandling af øjenforstyrrelser
EP2374472B9 (en) 2006-03-16 2019-06-12 Dyax Corp. Compositions and methods for treating ophthalmic disorders
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
WO2009030464A2 (de) * 2007-09-08 2009-03-12 Bayer Schering Pharma Aktiengesellschaft HERSTELLUNG UND VERWENDUNG VON VARIANTEN HUMANER KUNITZ-TYP PROTEASE-INHIBITOREN (hKTPI)
EP3281955A1 (en) 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
EA032828B1 (ru) * 2008-10-10 2019-07-31 Аптево Рисёрч Энд Девелопмент Ллс Иммунотерапевтические средства против комплекса tcr
ES2773766T3 (es) 2008-12-19 2020-07-14 Baxalta GmbH Inhibidores de TFPI y métodos de uso
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
DK2519543T3 (da) 2009-12-29 2016-09-26 Emergent Product Dev Seattle Heterodimerbindende proteiner og anvendelse heraf
LT2521568T (lt) * 2010-01-06 2018-12-10 Dyax Corp. Plazmos kalikreiną surišantys baltymai
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
CA2867363C (en) 2012-03-21 2023-02-28 Baxter International Inc. Tfpi inhibitors and methods of use
MX366813B (es) 2012-04-20 2019-07-25 Aptevo Res & Development Llc Polipeptidos de enlace cd3.
AU2013300549B2 (en) * 2012-08-08 2019-04-11 Daiichi Sankyo Company,Limited Peptide library and use thereof
ES2786253T3 (es) 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
CA2904444A1 (en) * 2013-03-15 2014-09-18 The Regents Of The University Of California Dual reactivity potent kunitz inhibitor of fibrinolysis
JP6543626B2 (ja) 2013-07-29 2019-07-10 ブルーバード バイオ， インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
CN105873952A (zh) 2013-10-31 2016-08-17 弗莱德哈钦森癌症研究中心 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
BR112016014156A8 (pt) 2013-12-20 2023-04-11 Hutchinson Fred Cancer Res Moléculas efetoras quiméricas etiquetadas e receptores das mesmas
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
CA2971430A1 (en) 2014-12-19 2016-06-23 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
EP3265481B1 (en) 2015-03-05 2024-05-01 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
AU2016366557B2 (en) 2015-12-11 2024-01-25 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
AU2017250295B2 (en) 2016-04-14 2022-08-25 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
ES2949364T3 (es) 2017-02-17 2023-09-28 Fred Hutchinson Cancer Center Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA
AU2018236461A1 (en) 2017-03-17 2019-09-19 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
EP3723787A4 (en) 2017-12-14 2021-09-01 Bluebird Bio, Inc. DARIC INTERLEUKIN RECEPTORS
US20220098613A1 (en) 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えａｄ３５ベクター及び関連遺伝子治療改善
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
EP4146695A1 (en) 2020-05-04 2023-03-15 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
DE2619246A1 (de) * 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2654124A1 (de) * 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
AU560584B2 (en) 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4657893A (en) 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en) 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
ES2066033T3 (es) 1989-05-13 1995-03-01 Bayer Ag Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
US7413537B2 (en) * 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
US5278285A (en) 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5278144A (en) 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
AU641568B2 (en) 1990-11-13 1993-09-23 Mochida Pharmaceutical Co., Ltd. Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
EP0637643A3 (en) * 1991-06-28 1995-04-19 Wecotec Ltd Transfer of cloths.
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
AU5684594A (en) 1992-12-02 1994-06-22 Novo Nordisk A/S Novel human amyloid protein precursor homologue and kunitz-type inhibitors
JP3929484B2 (ja) 1993-09-14 2007-06-13 ジェネンテック・インコーポレーテッド エコチンおよびその同族体を含む医薬的組成物
WO1995021601A2 (en) 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE529444T1 (de) 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
WO1997009989A1 (en) 1995-09-14 1997-03-20 Lxr Biotechnology Inc. Compositions with anti-apoptotic activity, containing a mixture of phospholipids
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
WO1997025422A1 (en) 1996-01-08 1997-07-17 Nissin Food Products Co., Ltd. Cancerous metastasis inhibitor
JP3357807B2 (ja) * 1997-01-13 2002-12-16 株式会社東芝 受信装置および移相器
US7383135B1 (en) * 1998-05-04 2008-06-03 Vertex Pharmaceuticals Incorporated Methods of designing inhibitors for JNK kinases
JP2000106882A (ja) 1998-10-02 2000-04-18 Chemo Sero Therapeut Res Inst 癌転移増殖抑制作用を有する血漿蛋白断片産生酵素および当該酵素により断片化された血漿蛋白断片
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
AU2003244516A1 (en) 2002-02-07 2003-09-02 Novozymes Delta Limited Hiv inhibiting proteins
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
PT2311432E (pt) 2002-06-07 2015-02-09 Dyax Corp Polipeptídeos de domínio kunitz modificado e sua utilização para a redução de isquemia ou aparecimento de uma resposta inflamatória sistémica associada a um procedimento cirúrgico
DK1542710T3 (da) 2002-08-28 2012-10-15 Dyax Corp Fremgangsmåde til konservering af organer og væv
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
AU2004204095B2 (en) 2003-01-07 2009-07-30 Dyax Corporation Kunitz domain library
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
WO2005021557A2 (en) 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors

Also Published As

Publication number Publication date
ES2375561T3 (es) 2012-03-02
US6010880A (en) 2000-01-04
US20080182283A1 (en) 2008-07-31
US20110152193A1 (en) 2011-06-23
JP4137997B2 (ja) 2008-08-20
US20090036365A1 (en) 2009-02-05
JP2013249302A (ja) 2013-12-12
WO1995018830A3 (en) 1995-08-10
US20030165896A1 (en) 2003-09-04
US6071723A (en) 2000-06-06
ES2229236T3 (es) 2005-04-16
US7919462B2 (en) 2011-04-05
JP2008113657A (ja) 2008-05-22
US6953674B2 (en) 2005-10-11
DE69533544T2 (de) 2006-02-23
US20050186649A1 (en) 2005-08-25
US6103499A (en) 2000-08-15
DK0737207T3 (da) 2005-01-31
WO1995018830A2 (en) 1995-07-13
JP2012111779A (ja) 2012-06-14
EP0737207B1 (en) 2004-09-22
US20090023651A1 (en) 2009-01-22
CA2180954C (en) 2007-03-20
CA2180954A1 (en) 1995-07-13
ATE529444T1 (de) 2011-11-15
US20090036366A1 (en) 2009-02-05
ATE277081T1 (de) 2004-10-15
US8431359B2 (en) 2013-04-30
EP0737207A1 (en) 1996-10-16
EP1489097A1 (en) 2004-12-22
PT737207E (pt) 2005-02-28
US6423498B1 (en) 2002-07-23
JP2009183281A (ja) 2009-08-20
EP1489097B1 (en) 2011-10-19
JPH09509048A (ja) 1997-09-16
DE69533544D1 (de) 2004-10-28
PT1489097E (pt) 2012-01-04

Similar Documents

Publication Publication Date Title
DK1489097T3 (da) Hæmmere af humant plasmin, der er afledt af kunitz-domæner, og nukleinsyrer, der koder for samme
DE68929430D1 (de) Fibronektin bindendes Protein
ES2194852T3 (es) Inhibidor de metaloproteinasa de tejido de tipo tres (timp-3).
DK217889A (da) Rekombinant-dna-udtrykkelsesvektorer og dna-forbindelser, der koder for desacetoxycephalosporin c synthetase
MY120693A (en) Human bikunin
DK672788A (da) Rekombinant-dna-vektorer til direkte udtrykkelse af aktiveret humant protein c
DK1017715T3 (da) Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse
DK0610260T3 (da) Vacciner mod Actinobacillus pleuropneumoniae
DK295188D0 (da) Fibronectinbindende protein og fremgangsmaade til fremstilling heraf
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
FI941851A (fi) Borrelia Burgdorferi -organismin (Bb) virulenssiin liittyvät proteiinit
DK723488A (da) Fremgangsmaade til rekombinant udtrykkelse af zymogene former af humant protein c samt vektorer, dna-forbindelser og transformanter til brug ved fremgangsmaaden
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
ATE128728T1 (de) Interferon-gamma bindende proteine.
DK278289A (da) Ekspressionsvektorer, deres fremstilling og anvendelse til fremstilling af ufusionerede proteiner i mikroorganismer
DK0941341T3 (da) Nukleotidsekvens, der koder for en flavinmonooxygenase, det tilsvarende protein og deres anvendelser inden for diagnostik og terapi
DK551786D0 (da) Rekombinant-dna-sekvens, der koder for aminosyresekvenser i et toksin, expressionssystem omfattende samme og vaertsceller transformeret hermed
DK0386733T3 (da) cDNA, som koder for placentaprotein 9 (PP9), dets isolering og anvendelse